Arthur He
Stock Analyst at HC Wainwright & Co.
(1.04)
# 3,435
Out of 4,760 analysts
54
Total ratings
31.37%
Success rate
-16.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Buy | $16 → $20 | $5.73 | +249.04% | 9 | Mar 10, 2025 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $1.91 | +423.56% | 6 | Mar 3, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Neutral | $2 → $1.5 | $1.35 | +11.11% | 9 | Feb 27, 2025 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $6.5 | $0.82 | +692.68% | 2 | Feb 25, 2025 | |
| ADAG Adagene | Maintains: Buy | $5 → $8 | $1.97 | +306.09% | 9 | Jan 27, 2025 | |
| HOOK HOOKIPA Pharma | Downgrades: Neutral | n/a | $1.25 | - | 7 | Jan 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $3.5 | $0.46 | +658.07% | 5 | Nov 19, 2024 | |
| BCAB BioAtla | Downgrades: Neutral | n/a | $0.34 | - | 7 | Nov 13, 2024 |
Solid Biosciences
Mar 10, 2025
Maintains: Buy
Price Target: $16 → $20
Current: $5.73
Upside: +249.04%
Prime Medicine
Mar 3, 2025
Reiterates: Buy
Price Target: $10
Current: $1.91
Upside: +423.56%
LAVA Therapeutics
Feb 27, 2025
Downgrades: Neutral
Price Target: $2 → $1.5
Current: $1.35
Upside: +11.11%
Nektar Therapeutics
Feb 25, 2025
Reiterates: Buy
Price Target: $6.5
Current: $0.82
Upside: +692.68%
Adagene
Jan 27, 2025
Maintains: Buy
Price Target: $5 → $8
Current: $1.97
Upside: +306.09%
HOOKIPA Pharma
Jan 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Adaptimmune Therapeutics
Nov 19, 2024
Reiterates: Buy
Price Target: $3.5
Current: $0.46
Upside: +658.07%
BioAtla
Nov 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.34
Upside: -